Incyte to Host EULAR Webcast and Conference Call on June 12WILMINGTON, Del.--(BUSINESS WIRE)--Jun 11, 2008 - Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled a webcast and conference call for 8:30 a.m. ET on Thursday, June 12, 2008 to discuss clinical results from a Phase IIa trial of INCB18424 in patients with rheumatoid arthritis that will be presented at the European League Against Rheumatism Congress 2008 currently being held in Paris.
The schedules for the press release, webcast and conference call are as follows: -0-
-- EULAR Press Release: June 12, 2008 at 7:00 a.m. ET -- EULAR Webcast & Conference Call: June 12, 2008 at 8:30 a.m. ET -- The live listen only webcast with slides of the presentation can be accessed on Incyte's website: http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-Calendar -- Analysts and investors are also invited to participate in the conference call by calling the following toll free numbers:-0-
Domestic Dial In Number: 877-407-8037 International Dial In Number: 201-689-8037 Conference ID #: 286637
If you are unable to participate, a replay of the webcast will be available on Incyte's website and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts.
Incyte is a Wilmington, Delaware-based drug discovery and development company with a growing pipeline of oral compounds to treat oncology, inflammation, diabetes and HIV. For additional information on Incyte visit the Company's web site at www.incyte.com.
Pamela M. Murphy
Investor Relations & Corporate Communications
Posted: June 2008